Participated · Series C · Jan 2026

FineHeart is a clinical-stage medical device company headquartered in Bordeaux and Tours that is building FlowMaker®, the first fully implantable cardiac output accelerator designed for advanced heart failure. The intraventricular pump synchronizes with native heart contractions, preserves physiological blood flow, and is wirelessly recharged via transcutaneous energy transfer, sharply lowering infection risk. Implantation is performed on a beating heart through a minimally invasive 90-minute procedure, giving surgeons a familiar workflow. The technology addresses a market of about 200,000 patients a year and initially targets the 50,000 most severe cases not served by current LVADs, an opportunity valued at more than €5 billion. FineHeart protects its platform with 160 patents across 27 families. With the latest funding, the company plans to industrialize FlowMaker® hardware, run clinical trials, and solidify its leadership in active implantable medical devices (AIMDs).

Participated · Equity · Jan 2021

Volta Medical's lead product, VOLTA VX1, is an AI decision-support tool that produces live, annotated 3D maps of cardiac anatomy and electrical activity by identifying abnormal intra-cardiac electrograms. The software is trained on curated databases of electrograms and is used during ablation procedures to help physicians identify and annotate heart abnormalities. Regulators in the US and EU have sanctioned the product as safe to use, and the company says it was the first to receive FDA clearance for interventional cardiology. Volta is preparing additional clinical trials, including a 342-patient study across three US hospitals expected to report in 2024, building on earlier follow-up studies that suggested a 73% improvement rate for atrial arrhythmia one year after surgery. The company plans to use new funding to support more clinical testing, full-scale US commercialisation, regulatory approvals in new markets, and follow-up products from its roadmap. Volta is headquartered in Marseille and is led by CEO and co-founder Theophile Mohr Durdez; the recent Series B brought total investment to above €70 million. Volta Medical develops AI software solutions to assist cardiac electrophysiologists, with its flagship product VX1 providing real-time identification of dispersed electrograms during procedures. VX1 is an FDA-cleared and CE-marked medical device intended to improve the management of cardiac arrhythmias and support ablation procedures. The company was founded in 2016 by three physicians and a data scientist and is led by CEO Theophile Mohr-Durdez. Volta describes VX1 as the first commercially available AI software for electrophysiologists and is preparing to transform how ablation procedures are performed. With the new financing, the company plans further R&D and to roll out commercial activities across the US and Europe. The product and regulatory clearances position Volta to pursue wider clinical adoption and commercial scale-up.